Jan de Vries, Ph.D.

Former Head of the Novartis Research Institutes for BioMedical Research

Jan de Vries, Ph.D., is the former Head of the Novartis Research Institutes for BioMedical Research in Basel, Switzerland. Prior to that, he was Head of the Novartis Research Institute in Vienna and Global Head of the Disease Area Autoimmunity, Transplantation and Inflammation.  While at Novartis, Dr. de Vries led the early development of many drugs that are now on the market or in late-stage clinical development, including Elidel® for the treatment of atopic dermatitis, Ilaris® (canakinumab) for the treatment of various chronic inflammatory diseases and diabetes, Gilenia® for the treatment of multiple sclerosis and AIN-457, an IL-17 mab for the treatment of autoimmune diseases.  Dr. de Vries joined Novartis from the DNAX Research Institute for Molecular Biological Research in Palo Alto, California, where he was director of the Immunology department from 1989-1997.  From 1985-1989, he was director of the Schering-Plough Institute for Immunological Research in Lyon, France.  He has held various academic positions at the Netherlands Cancer Institute in Amsterdam, where he was head of the Department of Immunology from 1979-1985.  Dr. de Vries received his Ph.D. in Immunology from the University of Amsterdam and spent two years as a visiting scientist at the University of California, San Diego.